A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142 · X-ACKT Phase 3Recruiting
- Lead sponsor
- Xenon Pharmaceuticals Inc. (Industry)
- Enrollment
- 160 (estimated)
- Start date
- 14 Feb 2023
- Primary completion
- Apr 2027 (estimated)
- Study completion
- 1 Jun 2027
- Last update posted
- 8 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Double
- Arms
- 3
Interventions
- XEN1101 Drug
- Placebo Drug
Conditions and primary outcome
- Primary Generalized Tonic-Clonic Seizures
Primary outcome
Median percent change (MPC) in monthly (28 days) PGTCS frequency (Baseline through DBP (Week 12))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05667142.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05667142 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.